RT Journal Article
SR Electronic
T1 The Persistence of Neutralising Antibodies up to 11 months after SARS-CoV-2 Infection in the Southern Region of New Zealand
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.26.21265501
DO 10.1101/2021.10.26.21265501
A1 McGregor, Reuben
A1 Craigie, Alyson
A1 Jack, Susan
A1 Upton, Arlo
A1 Moreland, Nicole J.
A1 Ussher, James
YR 2021
UL http://medrxiv.org/content/early/2021/10/27/2021.10.26.21265501.abstract
AB During the first wave of SARS-CoV-2 infection in New Zealand a cohort of 78 PCR-confirmed COVID-19 cases was recruited in the Southern District Health Board region. Here we report on this unique cohort nearly 1-year after infection. There was no known community transmission in the region over the study period due to New Zealand’s elimination status at the time, nor had any participants received a COVID-19 vaccine. In the absence of re-exposure, antibody reactivity to the viral spike protein, as well as neutralising antibodies to both the ancestral strain and the delta variant remained relatively stable between 8 and 11 months post-infection. This suggests long-lived antibody responses can be generated from a single natural infection event. However, given the risks of serious disease associated with SARS-CoV-2 infection, vaccination is still strongly recommended.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Southern Community Laboratories. This work was also funded in part by the School of Medicine Foundation (University of Auckland)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed at Southern Community Laboratories, Dunedin, NZ, in conjunction with the Southern District Health Board (SDHB), WellSouth (the local primary healthcare organisation), University of Otago, the University of Auckland. Ethical approval for this project was obtained from the NZ Health and Disability Ethics (HDEC) Committee (20/NTB/101)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors